Key result
Risk-adapted outpatient thromboprophylaxis using direct oral anticoagulants is recommended for high-risk patients with cancer to prevent venous thromboembolism.
Why the study?
Optimal thromboprophylaxis requires targeting high-risk cancer patients while avoiding low-risk patients, but major knowledge gaps and implementation barriers persist.
Does risk-adapted thromboprophylaxis prevent venous thromboembolism in high-risk patients with cancer?
Population
Patients with cancer
Design
Review
Authors
Loading...
May inform targeted DOAC use in high-risk cancer outpatients; leaves open need for further prospective validation.
Does risk-adapted thromboprophylaxis prevent venous thromboembolism in high-risk patients with cancer?
Risk-adapted outpatient thromboprophylaxis using direct oral anticoagulants is beneficial for high-risk cancer patients to prevent VTE, as supported by recent trials and updated guidelines.
Khorana et al. (2020) conducted a review in Cancer-associated thromboembolism. Risk-adapted thromboprophylaxis was evaluated. Risk-adapted outpatient thromboprophylaxis using direct oral anticoagulants is recommended for high-risk patients with cancer to prevent venous thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: